iSpecimen (NASDAQ: ISPC) notifies SEC of late 10-Q filing

Rhea-AI Filing Summary

iSpecimen Inc. notified the SEC that its Form 10-Q for the period ended March 31, 2026 will be filed late under Form 12b-25. The notification is dated May 15, 2026.

The company states the delay relates to items described in Part III and expects to file within the permitted cure period under Rule 12b-25; it includes a forward-looking statement disclaimer and is signed by CEO Katharyn Field.

Key Figures

Reporting period: March 31, 2026 Notification date: May 15, 2026 Cure period (quarterly): fifth calendar day +1 more

4 metrics

Reporting period March 31, 2026 Form 10-Q period end

Notification date May 15, 2026 Date signed on Form 12b-25

Cure period (quarterly) fifth calendar day Permitted cure period referenced for quarterly reports under Rule 12b-25

Contact phone 781-301-6700 Registrant contact number listed on the form

Key Terms

Form 12b-25, Form 10-Q, forward-looking statements

3 terms

Form 12b-25 regulatory

"Form 12b-25 NOTIFICATION OF LATE FILING (Check one)"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

Form 10-Q regulatory

"For Period Ended: March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

forward-looking statements financial

"This Form 12b-25 contains forward-looking statements that involve risks"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: March 31, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I

REGISTRANT INFORMATION

iSPECIMEN INC.

Full Name of Registrant

Former Name if Applicable

8 Cabot Road, Suite 1800

Address of Principal Executive Office (Street and Number)

Woburn, MA 08101

City, State and Zip Code

PART II

RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III

NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

iSpecimen Inc. (the “Company”) has determined that it will not be able to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 within the prescribed time period for such filing without unreasonable effort or expense. The Company is filing for the five calendar day extension period available under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

2

PART IV

OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Katharyn Field		781		301-6700
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Forward-looking Statements

This Form 12b-25 contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are identified by words such as “expects,” “intends” or other comparable terminology or by the context in which they are made. These forward-looking statements are estimates reflecting the best judgment of management and reflect our current expectations regarding the filing of the 2025 Form 10-Q. These expectations may or may not be realized. Some of these expectations may be based on beliefs, assumptions or estimates that may prove to be incorrect. In addition, our business and operations involve numerous risks and uncertainties, many of which are beyond our control, which could result in our expectations not being realized. Such risks and uncertainties include, but are not limited to, the risks and uncertainties described in greater detail in our filings with the Securities Exchange Commission. Any forward-looking statements contained herein speak only as of the date of this Form 12b-25 and we undertake no obligation to revise or update any forward-looking statements for any reason, except as required by law.

3

iSPECIMEN INC.

(Name of Registrant as Specified in its Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 15, 2026	By:	/s/ Katharyn Field
	Name:	Katharyn Field
	Title:	Chief Executive Officer

4

FAQ

Why did iSpecimen (ISPC) file a Form 12b-25?

To notify the SEC that its Form 10-Q for the period ended March 31, 2026, will be filed late. The filing cites reasons described in Part III and references management’s efforts to prepare the report within the Rule 12b-25 cure period.

When does iSpecimen expect to submit the late Form 10-Q?

The company indicates it expects to file within the cure period allowed by Rule 12b-25. The form references the statutory cure window tied to quarterly reports and the company’s stated timeline in Part III.

Who signed the Form 12b-25 for iSpecimen (ISPC)?

The Form 12b-25 is signed by Katharyn Field, Chief Executive Officer, and dated May 15, 2026. The signature attests that the company caused the notification to be filed on its behalf.

Does the Form 12b-25 include forward-looking statements from iSpecimen?

Yes, the notification contains forward-looking statements identified by words like “expects” and “intends.” It states such statements reflect management’s current expectations and carry risks and uncertainties.